Jonas Lauren Norr

The Promise of a Personal Medicine Factory

Jonas Lauren Norr

I can imagine a device no larger than a home printer, eventually smaller, that helps us understand and respond to our biology every day. A cheek swab, a urine sample, a small blood sample or another useful signal would enter one side. A precisely formulated intervention could emerge from the other: a tailored peptide, a nutritional supplement or another medicine, prepared for a particular person at a particular moment.

What interests me is the possibility of bringing measurement, interpretation and production into one continuous relationship with the body. Precision medicine could become something we live with, learning from our responses over time and helping us maintain function before a problem becomes a crisis.

The inputs would have different jobs. A cheek swab can supply cells for genetic testing, establishing information that generally does not need daily measurement.[1] Blood and urine could provide changing biochemical signals through appropriate assays. Hair would have a role only where a specific test has demonstrated meaningful information. Wearables could add sleep, activity and physiological trends. The machine would need to understand the timescale and reliability of each signal.

I would want it to build a personal baseline and recognize meaningful departures from it. A useful model would distinguish an ordinary fluctuation from a developing pattern, then test whether an intervention actually improved the outcome. The ambition is a more responsive relationship with our physiology. Daily observation could sometimes lead to the most useful decision of all: leave a healthy system alone.

A narrow version of this feedback loop already exists. Automated insulin delivery connects a glucose sensor, an algorithm and an insulin pump to adjust treatment for diabetes.[2] It delivers an existing medicine rather than manufacturing it, but demonstrates that measurement and treatment can operate together outside a hospital.

Research is also moving toward measuring a medicine alongside its effects. A 2025 Nature Communications study described a microneedle system that tracked glucose and metformin in interstitial fluid in rats.[3] This was an animal experiment, yet the underlying idea is compelling: observe both the intervention and the biological response. A future personal medicine system could use that relationship to learn how an individual processes a treatment.

The manufacturing side is becoming tangible. In 2020, MIT researchers reported automated tabletop synthesis of protein chains as long as 164 amino acids. Purification and folding remained additional steps.[4] A 2025 preprint describing MANGO presented a compact system that automated cell-free protein synthesis and purification, producing research and diagnostic proteins.[5] These are separate demonstrations of capabilities a future integrated device would need.

I can see a progression from dispensing carefully characterized ingredients to producing selected molecules locally. Early systems might use sealed cartridges containing established medicines or nutritional ingredients, adjusting the formulation within a clinically supported plan. Later generations could synthesize particular peptides when needed. Personalization could begin with the amount, timing and combination of known ingredients; inventing a new molecule for each person would require a much larger scientific leap.

The delivery format would be part of the invention. A nasal spray, an oral drink, a capsule and an intravenous preparation each present different challenges in absorption, stability and delivery. Research on oral semaglutide illustrates how much the formulation matters to getting a peptide into the body.[6] An injectable version would demand especially reliable purity and sterility. A useful machine would match the molecule, formulation and route to the intended biological effect.

The hardest scientific task may be deciding what to change. The body contains interacting systems with different response times. Moving a biomarker toward a target is valuable only if that change benefits the person. I would want these systems to earn broader capabilities through measured outcomes, beginning with well-understood relationships and gradually expanding what they can sense and influence.

The economic opportunity becomes interesting when personalization can be repeated without repeating an entire laboratory workflow. Standardized cartridges, reusable instruments and automated quality checks could reduce the labor involved in each cycle. Local production might also reduce waste from unused formulations or shorten the journey between a useful measurement and a response. Those potential savings would have to exceed the costs of consumables, maintenance, testing and the device itself.

My expectation is that the first compelling economics could appear in shared settings, such as clinics, where an instrument serves many people. Home versions could follow as reliability improves and recurring costs fall. There would also be logistical hurdles to overcome. The destination remains a small, accessible device whose value comes from better outcomes over time.

The possibility I find most exciting is medicine that becomes increasingly personal without becoming increasingly remote or complex to use. A compact biological observatory and medicine factory could help turn intermittent snapshots into an ongoing understanding of the body. That is a substantial scientific ambition, and one worth pursuing: making our ability to respond to biology as precise and adaptable as our ability to observe it.

Sources

Sources checked November 9, 2026.

[1] MedlinePlus Genetics, “How is genetic testing done?”. Accessed November 9, 2026.

[2] NIDDK, “Artificial Pancreas”. Accessed November 9, 2026.

[3] Yang et al., “Microneedle-based integrated pharmacokinetic and pharmacodynamic evaluation platform for personalized medicine,” Nature Communications. July 7, 2025.

[4] MIT News, “New technology enables fast protein synthesis”. May 28, 2020.

[5] da Silva et al., “Automated Cell-free Protein Synthesis for Distributed Biomanufacturing,” medRxiv preprint. October 17, 2025; preprint.

[6] Buckley et al., “Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist,” Science Translational Medicine. November 14, 2018.